The Bull Lives Below $1: PRSO, VTGN, ENSC, TNMG, QNME
https://thestreetreports.com/the-bull-lives-b...-to-watch/
Investor interest in low-priced growth stocks continues to build as companies across defense technology, artificial intelligence, biotechnology, digital media, and cross-border logistics announce significant business developments. Several stocks trading below the $1 level are attracting increased attention after releasing catalysts that could drive investor interest in the weeks ahead.
Peraso Inc. (NASDAQ: PRSO) remains one of the more closely watched names in the small-cap technology sector as investors continue to focus on the Company’s expanding opportunities in defense, autonomous systems, and artificial intelligence infrastructure. Peraso is a pioneer in high-performance 60 GHz mmWave wireless technology, with solutions designed for military drones, UAVs, autonomous systems, tactical communications, ISR missions, Identification Friend or Foe (IFF), electronic warfare, and AI-enabled battlefield networks. As governments worldwide continue increasing investments in next-generation defense communications and autonomous technologies, Peraso’s specialized wireless platform positions the Company within several rapidly expanding markets.
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) moved into focus after SRX Global Inc. (NYSE American: SRXH) announced it has acquired a strategic stake in the late clinical-stage neuroscience company. Vistagen is pioneering a new class of intranasal therapies known as pherines, utilizing nose-to-brain neurocircuitry designed to address significant unmet needs in neuroscience. The investment highlights growing institutional interest in innovative biotechnology companies developing differentiated therapeutic platforms while reinforcing confidence in Vistagen’s clinical pipeline.
Ensysce Biosciences, Inc. (NASDAQ: ENSC) announced it has received a $5.3 million Notice of Award from the National Institute on Drug Abuse (NIDA), marking the third consecutive year of federal funding supporting development of its proprietary MPAR® (Multi-Pill Abuse Resistance) overdose-protection technology. The latest award completes approximately $15.1 million in total funding dedicated to advancing PF614-MPAR, the Company’s breakthrough opioid candidate engineered with a built-in chemical safety mechanism designed to automatically limit opioid release when excessive doses are consumed. PF614-MPAR previously received FDA Breakthrough Therapy designation, positioning Ensysce among the innovators seeking safer alternatives amid the ongoing opioid crisis.
TNL Mediagene (NASDAQ: TNMG) announced a strategic partnership with Miro, the AI-powered innovation workspace company, as part of its fiscal 2026 strategy to accelerate AI-powered enterprise services. Through its Japan-based digital studio Infobahn, TNL Mediagene will integrate its established design thinking, innovation consulting, service design, and prototyping methodologies with Miro’s advanced AI workspace featuring multi-modal capabilities, real-time collaboration, and MCP integration. The partnership is designed to help enterprise customers modernize organizational design, human resource development, and innovation initiatives while expanding the Company’s presence in the rapidly growing AI productivity market throughout Asia.
Quanome Technologies, Inc. (NASDAQ: QNME) also attracted trader attention after experiencing unusually heavy trading volume during early market activity. The Company operates an integrated cross-border supply chain platform with a strategic emphasis on China, South Korea, and broader Asian markets, providing logistics and supply chain solutions that support international commerce. Increased trading activity has placed the stock on momentum watchlists as investors monitor whether volume continues to build throughout the session.
As capital continues rotating into emerging growth companies trading below $1, investors are increasingly searching for businesses with meaningful operational catalysts across defense technology, biotechnology, artificial intelligence, enterprise software, and global logistics. Companies including Peraso (NASDAQ: PRSO), Vistagen Therapeutics (NASDAQ: VTGN), Ensysce Biosciences (NASDAQ: ENSC), TNL Mediagene (NASDAQ: TNMG), and Quanome Technologies (NASDAQ: QNME) represent diverse sectors where recent corporate developments have positioned each stock among the low-priced companies investors are watching closely.
https://thestreetreports.com/the-bull-lives-b...-to-watch/
Investor interest in low-priced growth stocks continues to build as companies across defense technology, artificial intelligence, biotechnology, digital media, and cross-border logistics announce significant business developments. Several stocks trading below the $1 level are attracting increased attention after releasing catalysts that could drive investor interest in the weeks ahead.
Peraso Inc. (NASDAQ: PRSO) remains one of the more closely watched names in the small-cap technology sector as investors continue to focus on the Company’s expanding opportunities in defense, autonomous systems, and artificial intelligence infrastructure. Peraso is a pioneer in high-performance 60 GHz mmWave wireless technology, with solutions designed for military drones, UAVs, autonomous systems, tactical communications, ISR missions, Identification Friend or Foe (IFF), electronic warfare, and AI-enabled battlefield networks. As governments worldwide continue increasing investments in next-generation defense communications and autonomous technologies, Peraso’s specialized wireless platform positions the Company within several rapidly expanding markets.
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) moved into focus after SRX Global Inc. (NYSE American: SRXH) announced it has acquired a strategic stake in the late clinical-stage neuroscience company. Vistagen is pioneering a new class of intranasal therapies known as pherines, utilizing nose-to-brain neurocircuitry designed to address significant unmet needs in neuroscience. The investment highlights growing institutional interest in innovative biotechnology companies developing differentiated therapeutic platforms while reinforcing confidence in Vistagen’s clinical pipeline.
Ensysce Biosciences, Inc. (NASDAQ: ENSC) announced it has received a $5.3 million Notice of Award from the National Institute on Drug Abuse (NIDA), marking the third consecutive year of federal funding supporting development of its proprietary MPAR® (Multi-Pill Abuse Resistance) overdose-protection technology. The latest award completes approximately $15.1 million in total funding dedicated to advancing PF614-MPAR, the Company’s breakthrough opioid candidate engineered with a built-in chemical safety mechanism designed to automatically limit opioid release when excessive doses are consumed. PF614-MPAR previously received FDA Breakthrough Therapy designation, positioning Ensysce among the innovators seeking safer alternatives amid the ongoing opioid crisis.
TNL Mediagene (NASDAQ: TNMG) announced a strategic partnership with Miro, the AI-powered innovation workspace company, as part of its fiscal 2026 strategy to accelerate AI-powered enterprise services. Through its Japan-based digital studio Infobahn, TNL Mediagene will integrate its established design thinking, innovation consulting, service design, and prototyping methodologies with Miro’s advanced AI workspace featuring multi-modal capabilities, real-time collaboration, and MCP integration. The partnership is designed to help enterprise customers modernize organizational design, human resource development, and innovation initiatives while expanding the Company’s presence in the rapidly growing AI productivity market throughout Asia.
Quanome Technologies, Inc. (NASDAQ: QNME) also attracted trader attention after experiencing unusually heavy trading volume during early market activity. The Company operates an integrated cross-border supply chain platform with a strategic emphasis on China, South Korea, and broader Asian markets, providing logistics and supply chain solutions that support international commerce. Increased trading activity has placed the stock on momentum watchlists as investors monitor whether volume continues to build throughout the session.
As capital continues rotating into emerging growth companies trading below $1, investors are increasingly searching for businesses with meaningful operational catalysts across defense technology, biotechnology, artificial intelligence, enterprise software, and global logistics. Companies including Peraso (NASDAQ: PRSO), Vistagen Therapeutics (NASDAQ: VTGN), Ensysce Biosciences (NASDAQ: ENSC), TNL Mediagene (NASDAQ: TNMG), and Quanome Technologies (NASDAQ: QNME) represent diverse sectors where recent corporate developments have positioned each stock among the low-priced companies investors are watching closely.
